Actinium Pharmaceuticals' (ATNM) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Free Report) in a report released on Monday, Benzinga reports. The brokerage currently has a $50.00 price target on the biotechnology company’s stock. HC Wainwright also issued estimates for Actinium Pharmaceuticals’ Q2 2024 earnings at ($0.38) EPS, Q3 2024 earnings at ($0.45) […]

Related Keywords

,News Ratings For Actinium Pharmaceuticals Daily ,Brandywine Global Investment Management ,Creative Financial Designs Inc ,Cantor Fitzgerald ,Actinium Pharmaceuticals Inc ,Actinium Pharmaceuticals ,Analyst Recommendations For Actinium Pharmaceuticals ,Actinium Pharmaceuticals Stock Performance ,Sanders Morris Harris ,Hedge Funds Weigh In On Actinium Pharmaceuticals ,Maxim Group ,Free Report ,Moderate Buy ,Get Free Report ,Global Investment Management ,Morris Harris ,Creative Financial Designs ,Financial Designs ,Actinium Pharmaceuticals Daily ,Nyseamerican Atnm ,Atnm ,Medical ,Reiterated Rating ,Hc Wainwright ,